London, United Kingdom
RQ Biotechnology Ltd., founded in 2022 and headquartered in the United Kingdom, is a biotechnology company that focuses on the healthcare industry. The company's slogan, "RQ Bio: Helping Protect Vulnerable Populations Through Instant Immunity Antibodies," reflects its mission to provide instant and long-lasting protection for vulnerable populations against infectious diseases. RQ Biotechnology is at the forefront of passive immunization discovery, collaborating with pharmaceutical companies to develop antibodies that offer protection where vaccines fall short.
The company is dedicated to developing potent broad-spectrum monoclonal antibodies (mAbs) to address the needs of individuals at risk of severe disease or death from current and future viral infections. This focus on instant immunity positions RQ Biotechnology as a critical player in the biotechnology space, particularly in the context of addressing global health challenges.
While specific details about the company's last investment and the involved investors have not been disclosed at this time, RQ Biotechnology's innovative approach to addressing the gap in protection from infectious diseases presents an exciting opportunity for potential investors and pharmaceutical collaborators. The company's commitment to developing solutions for vulnerable populations underscores its potential impact on public health and societal well-being.
